{"id":5735,"date":"2026-08-05T07:39:14","date_gmt":"2026-08-05T07:39:14","guid":{"rendered":"https:\/\/echeloncreativemedia.com\/marketvows\/2026\/08\/05\/novo-nordisk-stock-dips-despite-rosier-forecast-long-term-obesity-pipeline-questions-linger\/"},"modified":"2026-08-05T07:39:14","modified_gmt":"2026-08-05T07:39:14","slug":"novo-nordisk-stock-dips-despite-rosier-forecast-long-term-obesity-pipeline-questions-linger","status":"publish","type":"post","link":"https:\/\/echeloncreativemedia.com\/marketvows\/2026\/08\/05\/novo-nordisk-stock-dips-despite-rosier-forecast-long-term-obesity-pipeline-questions-linger\/","title":{"rendered":"Novo Nordisk Stock Dips Despite Rosier Forecast; Long-Term Obesity Pipeline Questions Linger"},"content":{"rendered":"

Novo Nordisk saw its stock fall despite raising its full-year forecast, as analysts pointed to temporary factors boosting its quarterly beat and ongoing concerns about its long-term obesity drug pipeline amidst fierce competition from Eli Lilly. The company also reported another mixed clinical result for its next-generation weight-loss drug, CagriSema, further fueling investor doubts.<\/p>\n

Although Novo Nordisk hiked its guidance, citing strong expectations for its GLP-1 products like Wegovy, the market remains focused on the company’s ability to innovate and compete effectively against rivals like Eli Lilly’s Zepbound and Mounjaro.<\/p>\n

<\/p>\n

READ MORE FROM CNBC<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Novo Nordisk saw its stock fall despite raising its full-year forecast, as analysts pointed to temporary factors boosting its quarterly beat and ongoing concerns about its long-term obesity drug pipeline amidst fierce competition from Eli Lilly. The company also reported another mixed clinical result for its next-generation weight-loss drug, CagriSema, further fueling investor doubts. Although […]<\/p>\n","protected":false},"author":1,"featured_media":5736,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/fm.cnbc.com\/a\/img\/resize\/sh\/media\/2023\/04\/06\/1680817882-0406-sm-novo-nordisk-nvo.cf2.jpg?width=1024&resizeMethod=fit&__source=cnbc","fifu_image_alt":"","footnotes":""},"categories":[28,29],"tags":[],"class_list":["post-5735","post","type-post","status-publish","format-standard","has-post-thumbnail","category-economy","category-global-affairs","rifnote_country-denmark","rifnote_country-united-states","rifnote_executive-david-ricks","rifnote_executive-mike-doustdar"],"fifu_image_url":"https:\/\/fm.cnbc.com\/a\/img\/resize\/sh\/media\/2023\/04\/06\/1680817882-0406-sm-novo-nordisk-nvo.cf2.jpg?width=1024&resizeMethod=fit&__source=cnbc","_links":{"self":[{"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/posts\/5735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/comments?post=5735"}],"version-history":[{"count":0,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/posts\/5735\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/media\/5736"}],"wp:attachment":[{"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/media?parent=5735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/categories?post=5735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/tags?post=5735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}